We are live on ! Find out more
ABMD

Abiomed Inc

Delisted

ABMD was delisted on the 21st of December, 2022.

495 hedge funds and large institutions have $10.5B invested in Abiomed Inc in 2022 Q2 according to their latest regulatory filings, with 65 funds opening new positions, 188 increasing their positions, 153 reducing their positions, and 60 closing their positions.

New
Increased
Maintained
Reduced
Closed

23% more repeat investments, than reductions

Existing positions increased: 188 | Existing positions reduced: 153

8% more first-time investments, than exits

New positions opened: 65 | Existing positions closed: 60

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

1% less funds holding

Funds holding: 500495 (-5)

24% less call options, than puts

Call options by funds: $40.4M | Put options by funds: $53.2M

25% less capital invested

Capital invested by funds: $14B → $10.5B (-$3.46B)

Holders
495
Holders Change
-5
Holders Change %
-1%
% of All Funds
8.31%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
65
Increased
188
Reduced
153
Closed
60
Calls
$40.4M
Puts
$53.2M
Net Calls
-$12.8M
Net Calls Change
-$28.5M

ABMD Hedge Fund Activity: Q2 2022 in Review

495 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Abiomed Inc (ABMD) for Q2 2022, worth a combined $10.5B — down 25% from $14B a quarter earlier.

Buyers outnumbered sellers: 65 funds opened new ABMD positions and 60 closed out — a net gain of 5 holders — while 188 added to existing stakes and 153 trimmed.

The largest buyer was Winslow Capital Management, adding an estimated $101M. The largest seller was Wellington Management Group, cutting an estimated $194M.

  • 495 institutional investors held Abiomed Inc (ABMD) as of Q2 2022, down from 500 in Q1 2022.
  • Funds reported $10.5B of Abiomed Inc stock for Q2 2022, down 25% quarter-over-quarter.
  • 65 funds opened new Abiomed Inc positions in Q2 2022 and 60 closed out, a net change of +5 holders.
  • The largest Abiomed Inc buyer in Q2 2022 was Winslow Capital Management, an estimated $101M added.
  • The largest Abiomed Inc seller in Q2 2022 was Wellington Management Group, an estimated $194M sold.

Based on aggregated 13F filings for Q2 2022.